Diabetologia

, Volume 55, Issue 12, pp 3399–3400

Erratum to: Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials

  • R. J. Stevens
  • R. Ali
  • C. R. Bankhead
  • M. A. Bethel
  • B. J. Cairns
  • R. P. Camisasca
  • F. L. Crowe
  • A. J. Farmer
  • S. Harrison
  • J. A. Hirst
  • P. Home
  • S. E. Kahn
  • J. H. McLellan
  • R. Perera
  • A. Plüddemann
  • A. Ramachandran
  • N. W. Roberts
  • P. W. Rose
  • A. Schweizer
  • G. Viberti
  • R. R. Holman
Erratum

DOI: 10.1007/s00125-012-2740-9

Cite this article as:
Stevens, R.J., Ali, R., Bankhead, C.R. et al. Diabetologia (2012) 55: 3399. doi:10.1007/s00125-012-2740-9

Erratum to: Diabetologia

DOI 10.1007/s00125-012-2653-7

The authors regret a single data transcription error at the co-ordinating centre that resulted in numerical errors in several of the reported hazard ratios for all-cause mortality. The correct values (shown in red font) in the text should have been:

Abstract: The summary RR for all-cause mortality was https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figa_HTML.gif (95% CI https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figb_HTML.gif, https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figc_HTML.gif) across all trials.

Results, All-cause mortality: RRs for all-cause mortality could be obtained for 13 trials, representing 66,447 person-years of follow-up during which https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figd_HTML.gif deaths were recorded. … The summary RR for all-cause mortality in people randomised to metformin compared with all comparators was https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Fige_HTML.gif (95% CI https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figf_HTML.gif, https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figg_HTML.gif). The summary RR for all-cause mortality was 0.91 (95% CI 0.70, 1.18) in trials comparing metformin to placebo/usual care and https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figh_HTML.gif (95% CI https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figi_HTML.gif, https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figj_HTML.gif) in trials comparing metformin to active comparators (Fig. 3). The summary RR from 1-year trials was 0.84 (95% CI 0.52, 1.38) and the summary RR from trials longer than 1 year was https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figk_HTML.gif (95% CI https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figl_HTML.gif, https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figm_HTML.gif). In a post hoc sensitivity analysis, excluding the UKPDS sulfonylurea trial had the effect of reducing the RR for all-cause mortality in metformin compared with placebo/usual care to 0.67 (95% CI 0.49, 0.93; I2 0.0%), and in metformin compared with any comparator to https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Fign_HTML.gif (95% CI https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figo_HTML.gif, https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figp_HTML.gif; I2 0.0%).
https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Fig1_HTML.gif
Fig. 3

RRs (squares) and 95% CIs (horizontal bars) for all-cause mortality in participants in RCTs randomised to metformin compared with comparators, stratified by comparator type, with summary estimates and 95% CIs (diamonds). aNote that the ADOPT-G and ADOPT-R lines represent multiple comparisons from a single trial, and the analysis takes account of correlation between these comparisons: see original text for details

A corrected version of Fig. 3 is shown above.

In addition, a typographical error appeared in Fig. 2. In the ‘Study’ column ‘EDIT-A [43]’ should have read ‘EDIT [43]’.

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • R. J. Stevens
    • 1
  • R. Ali
    • 2
  • C. R. Bankhead
    • 1
  • M. A. Bethel
    • 3
  • B. J. Cairns
    • 2
  • R. P. Camisasca
    • 4
  • F. L. Crowe
    • 2
  • A. J. Farmer
    • 1
  • S. Harrison
    • 1
  • J. A. Hirst
    • 1
  • P. Home
    • 5
  • S. E. Kahn
    • 6
  • J. H. McLellan
    • 1
  • R. Perera
    • 1
  • A. Plüddemann
    • 1
  • A. Ramachandran
    • 7
  • N. W. Roberts
    • 1
  • P. W. Rose
    • 1
  • A. Schweizer
    • 8
  • G. Viberti
    • 9
  • R. R. Holman
    • 3
  1. 1.Department of Primary Care Health SciencesUniversity of OxfordOxfordUK
  2. 2.Cancer Epidemiology UnitUniversity of OxfordOxfordUK
  3. 3.Diabetes Trials Unit, Oxford Centre for Diabetes Endocrinology and MetabolismUniversity of OxfordOxfordUK
  4. 4.TGRD Europe, Takeda Pharmaceutical CompanyLondonUK
  5. 5.ICM–Diabetes, The Medical SchoolNewcastle UniversityNewcastle upon TyneUK
  6. 6.Division of Metabolism, Endocrinology and Nutrition, Department of MedicineVeterans Affairs Puget Sound Health Care System and University of WashingtonSeattleUSA
  7. 7.India Diabetes Research FoundationDr A. Ramachandran’s Diabetes HospitalsChennaiIndia
  8. 8.Novartis PharmaBaselSwitzerland
  9. 9.Unit for Metabolic Medicine, School of MedicineKing’s College LondonLondonUK